App-Quantinova.ai

Statins as Potential Farnesoid X Receptor Modulators in Atrial Cardiomyocytes: A Gender, Age and miR328 Controlled Response

James Tsoporis - American Heart Association (AHA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

N/A

Over-Expression of Insulin-Like Growth Factor-1 by Human Cardiac Stem Cells Enhances Long-Term Retention of Transplanted Cells While Promoting Salvage of Injured Myocardium

Everad L Tilokee - American Heart Association (AHA) , 2014

Therapeutic Area

Disease

Drug/Treatment

N/A

Mecasermin

Incremental Prognostic Value of Echocardiographic Markers of Left Ventricular Remodeling and Diastolic Function in the Surgical Treatment for Ischemic Heart Failure Trial

Lilin She - American Heart Association (AHA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Coronary Artery Disease

N/A

PCSK9 R46L, Lower LDL and Cardiovascular Disease Risk in Familial Hypercholesterolemia

Alexis Baass - American Heart Association (AHA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Hypercholesterolemia, Familial, 1

N/A

Real Time MRI Based Atrial Cryoablation

Eugene Kholmovski - American Heart Association (AHA) , 2014

Therapeutic Area

Disease

Drug/Treatment

N/A

PKR-Like Endoplasmic Reticulum Kinase (PERK) and Glycogen Synthase Kinase (GSK)-3?/? Signaling Regulate Atherosclerosis Development

Geoff Werstuck - American Heart Association (AHA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

Thapsigargin

Pulse Pressure and Intraluminal Mean Pressure Regulate Endothelium-Dependent Flow-Mediated Dilation in Cerebral Arteries of Dyslipidemic Mice

Virginie Bolduc - American Heart Association (AHA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Vasodilation dysfunction

N/A

Activation of TRAF2-NF-?B Signaling suppresses Mitochondrial Perturbations in Doxorubicin Cardiotoxicity

Lorrie A Kirshenbaum - American Heart Association (AHA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Cardiotoxicity

Doxorubicin

Validation of a of Self-Reported Measure of Physical Capacity in the Context of Chronic Cardiovascular and Pulmonary Diseases

Paul Poirier Dr - American Heart Association (AHA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Interstitial lung disease

N/A

PCSK9 Inhibitor Alirocumab as Add-on to Atorvastatin versus Other Lipid Treatment Strategies in Patients at High CVD Risk: ODYSSEY OPTIONS I

Daniel Gaudet - American Heart Association (AHA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetes

Atorvastatin

Ecto-Nucleotidase-Derived Adenosine Promotes Mineralization Through A2a Receptor in Calcified Aortic Valves Disease

Marie-Chloe Boulanger - American Heart Association (AHA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Calcific Aortic Valve Disease

Adenosine

PI3K? Has a Role in Myocardial Insulin Signaling and Recovery From Cre/Tamoxifen Cardiotoxicity, but is not Required for Normal Function in the Adult Mouse Heart

Pavel Zhabyeyev - American Heart Association (AHA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Systolic dysfunction

Tamoxifen

A Novel Class of Inhibitors That Are Specific to Human NPP1 Prevent Pathologic Mineralization of Valve Interstitial Cells

Elsa Forcellini - American Heart Association (AHA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Calcific Aortic Valve Disease

N/A

Role of Long Non-Coding RNAs in the Regulation of the Notch Pathway: Implication for Calcific Aortic Valve Stenosis

M Boulanger - American Heart Association (AHA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Cardiac valvular dysplasia X-linked

N/A

Right Ventricular Energetics and Power in Pulmonary Regurgitation vs. Stenosis Using Four-Dimensional Phase-Contrast Magnetic Resonance

Joao Filipe Fernandes - American Heart Association (AHA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Pulmonary regurgitation

N/A

Evaluation of the Relationship of Functional Survival with the Three-phase Model of Out-Of-Hospital Cardiac Arrest in the Era of Targeted Temperature Management

Kevin E. Thorpe - American Heart Association (AHA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Cardiac arrest

N/A

External Validation of the Hypothermic to Ischemic Ratio as a Predictor of Survival from Out-of-Hospital Cardiac Arrest for Patients Presenting with a Shockable Rhythm

Michael C Kurz - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Cardiac arrest

N/A

Barriers to Implementation of the PulsePoint Smartphone Application

Heather C Worthington - American Heart Association (AHA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Cardiac arrest

N/A

Does Neighborhood Really Matter? How Location Influences Bystander CPR Rates

Joel G Ray - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Cardiac arrest

N/A

Predicting Aortic Aneurysm Rupture: A Computational Fluid Dynamics Analysis

David C Kuhn - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Abdominal aortic aneurysm

N/A

Filters

28841 Abstracts